Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. L'Air Liquide S.A.
  6. News
  7. Summary
    AI   FR0000120073


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gases firm Linde boosted by healthcare, ramps up oxygen production

05/06/2021 | 12:47pm EDT
FILE PHOTO: Men park Linde tankers after they arrived from abroad to help with coronavirus disease (COVID-19) crisis, in Kolkata

(Reuters) - Linde, the world's largest industrial gases company, hiked its 2021 earnings outlook on Thursday, as a strong performance in its healthcare business helped it beat first quarter forecasts.

The U.S.-German company, which supplies gases such as oxygen, nitrogen and hydrogen to factories and hospitals, now expects adjusted earnings per share to rise 17-19% year-on-year - compared with its previous forecast for 11-13% growth.

Higher prices and growing demand in the healthcare sector - where Linde supplies equipment and medical gases including oxygen for COVID-19 patients - helped its sales in Europe, the Middle East and Africa jump 10% in the first quarter.

The pandemic has driven up demand for medical oxygen, particularly in India, where severe shortages and logistics problems have seen dozens of hospitals run short in recent weeks.

Chief Operating Officer Sanjiv Lamba said that teams in India were now producing more than 3,000 tonnes of medical oxygen daily, nearly ten-fold the figure four weeks ago.

"We've deployed about 1,200 drivers on the road, serving about 1,000 hospitals in the country," he added.

Linde, India's biggest oxygen producer, and other suppliers are ramping up production to more than 9,000 tonnes per day by mid-May, an executive told Reuters last week.

Lamba noted similar challenges in Mexico, Brazil and other Latin American countries - where infections continue to spread, filling up intensive care units, even as restrictions ease.

Linde's overall earnings per share for January-March rose 32% to $2.49, beating analysts' average estimate of $2.26 and its own guidance.

Linde's biggest competitor, Air Liquide, also beat analysts' forecasts last month, driven by strong demand for medical oxygen and an industrial rebound in China.

(Reporting by Sarah Morland and Veronica Snoj in Gdansk. Editing by Mark Potter, Kirsten Donovan)

By Sarah Morland and Veronica Snoj

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
DOW JONES AFRICA TITANS 50 INDEX -0.93% 525.56 Delayed Quote.-0.77%
EURO / BRAZILIAN REAL (EUR/BRL) 0.83% 6.0361 Delayed Quote.-5.65%
L'AIR LIQUIDE S.A. -0.59% 144.6 Real-time Quote.7.71%
S&P AFRICA 40 INDEX -1.27% 168.56 Delayed Quote.-2.69%
All news about L'AIR LIQUIDE S.A.
06/15ANALYST RECOMMENDATIONS : Anglo American, Pfizer, Rolls-Royce, Nike, Oatly...
06/14SECTOR UPDATE : Energy Stocks Trade Higher Premarket Monday
06/14SECTOR UPDATE : Energy
06/14SASOL  : Obtains South African Court Approval for Air Liquide Transaction
06/10AIR LIQUIDE : Voting Rights
06/09AIR LIQUIDE(L)  : Barclays maintains a Buy rating
06/07AIR LIQUIDE(L)  : Credit Suisse keeps its Buy rating
06/03AIR LIQUIDE  : and Severstal extend their partnership with a new long-term contr..
06/01AIR LIQUIDE  : Appointments
05/28Hydrogen 'a huge opportunity' to replace fossil fuels, says U.S. energy secre..
More news
Sales 2021 21 526 M 25 528 M 25 528 M
Net income 2021 2 617 M 3 104 M 3 104 M
Net Debt 2021 10 995 M 13 040 M 13 040 M
P/E ratio 2021 26,2x
Yield 2021 2,03%
Capitalization 68 248 M 80 911 M 80 937 M
EV / Sales 2021 3,68x
EV / Sales 2022 3,46x
Nbr of Employees 64 445
Free-Float 97,1%
Duration : Period :
L'Air Liquide S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends L'AIR LIQUIDE S.A.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 155,94 €
Last Close Price 144,60 €
Spread / Highest target 31,4%
Spread / Average Target 7,84%
Spread / Lowest Target -10,1%
EPS Revisions
Managers and Directors
Benoît Potier Chairman & Chief Executive Officer
Jerome Jenamarie Pelletan Chief Financial Officer
Jean-Paul Agon Lead Independent Director
Siân Herbert-Jones Independent Director
Sin Leng Low Independent Director
Sector and Competitors